Attached files
file | filename |
---|---|
EX-10.1 - AMENDMENT AGREEMENT, DATED JULY 1, 2020, BY AND BETWEEN THE COMPANY AND LOMA LIN - Aditxt, Inc. | f10q0620ex10-1_aditxtherape.htm |
10-Q - QUARTERLY REPORT - Aditxt, Inc. | f10q0620_aditxtherape.htm |
EX-32.1 - CERTIFICATION - Aditxt, Inc. | f10q0620ex32-1_aditxtherape.htm |
EX-31.2 - CERTIFICATION - Aditxt, Inc. | f10q0620ex31-2_aditxtherape.htm |
EX-31.1 - CERTIFICATION - Aditxt, Inc. | f10q0620ex31-1_aditxtherape.htm |
EX-3.2 - CERTIFICATE OF AMENDMENT, DATED JUNE 29, 2020 - Aditxt, Inc. | f10q0620ex3-2_aditxtherape.htm |
EXHIBIT 32.2
CERTIFICATIONS
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (A) and (B) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), I, Corinne Pankovcin, Chief Financial Officer of Aditx Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certify, to my knowledge, that:
The Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 (the “Form 10-Q”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: August 13, 2020 | By: | /s/ Corinne Pankovcin |
Name: | Corinne Pankovcin | |
Title: | Chief
Financial Officer |